Haemonetics Corporation reported a strong financial performance for the second quarter of fiscal 2025 with revenues reaching $346 million, a 9% increase year-over-year, and an adjusted EPS of $1.12, up 13% compared to the prior year. This performance was predominantly driven by significant growth in the hospital segment, particularly through enhanced offerings in blood management technologies, which saw a 31% revenue increase. The company is navigating the transition challenges associated with its key customer, CSL, impacting plasma revenues, but remains optimistic about market positioning and ongoing share gains in a competitive environment.
Management is raising its organic growth guidance due to positive momentum in the hospital business, while closely managing expenses and optimizing operations to ensure sustained profitability. The overall sentiment reflects confidence in achieving long-term strategic goals despite near-term market fluctuations.